Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Differential improvement in survival among patients with AIDS after the introduction of HAART.

Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, Cazein F, Vittecoq D, Desenclos JC; Aids Survival Study Group..

AIDS Care. 2007 Apr;19(4):523-31.

PMID:
17453593
2.

Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia.

Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM; National HIV Surveillance Committee..

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):388-95. Erratum in: J Acquir Immune Defic Syndr 2002 Jul 1;30(3):368. Kaldo, John M [corrected to Kaldor, John M].

PMID:
11917244
3.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study..

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
4.

Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.

Girardi E, Palmieri F, Cingolani A, Ammassari A, Petrosillo N, Gillini L, Zinzi D, De Luca A, Antinori A, Ippolito G.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):326-31.

PMID:
11317073
5.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group..

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
6.

Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group.

Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli R, Lazzeri V, Rezza G.

AIDS. 1999 Feb 4;13(2):249-55.

PMID:
10202831
7.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
8.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group..

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
9.

Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.

Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR Jr, Detels R.

Am J Epidemiol. 2006 Feb 15;163(4):310-5. Epub 2005 Dec 21.

PMID:
16371516
10.
11.

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators..

J Acquir Immune Defic Syndr. 2006 Sep;43(1):27-34.

PMID:
16878047
12.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)..

HIV Med. 2005 May;6(3):198-205.

13.

Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. Lazio AIDS Surveillance Collaborative Group.

Porta D, Rapiti E, Forastiere F, Pezzotti P, Perucci CA.

AIDS. 1999 Oct 22;13(15):2125-31.

PMID:
10546866
14.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

PMID:
17763327
15.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
16.

Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.

Yang CH, Huang YF, Hsiao CF, Yeh YL, Liou HR, Hung CC, Yang SY.

HIV Med. 2008 Aug;9(7):535-43. doi: 10.1111/j.1468-1293.2008.00600.x. Epub 2008 Jun 28.

17.

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, Hernàndez-Aguado I; GEMES (Spanish Multicenter Study Group of Seroconverters)..

AIDS. 2003 Feb 14;17(3):353-9.

PMID:
12556689
18.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
19.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
20.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

Supplemental Content

Support Center